J. Gong

Journal of Immunotherapy for Cancer · with Chehrazi-Raffle · 2018

A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from J. Gong's perspective

Ordered by how strongly the researchers J. Gong trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)
  2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  3. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
  4. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
  5. Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (New England Journal of Medicine)
  6. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (New England Journal of Medicine)
  7. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
  8. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
  9. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
  10. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (The Lancet Oncology)

Their papers